Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-115123
Filing Date
2026-03-19
Accepted
2026-03-19 07:10:31
Documents
91
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K acrv-20251231.htm   iXBRL 10-K 3059860
2 EX-4.1 acrv-ex4_1.htm EX-4.1 50117
3 EX-19.1 acrv-ex19_1.htm EX-19.1 180554
4 EX-21.1 acrv-ex21_1.htm EX-21.1 3587
5 EX-23.1 acrv-ex23_1.htm EX-23.1 3986
6 EX-31.1 acrv-ex31_1.htm EX-31.1 17996
7 EX-31.2 acrv-ex31_2.htm EX-31.2 17963
8 EX-32.1 acrv-ex32_1.htm EX-32.1 11862
9 EX-32.2 acrv-ex32_2.htm EX-32.2 11824
10 GRAPHIC img230064954_0.jpg GRAPHIC 101267
  Complete submission text file 0001193125-26-115123.txt   12398081

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20251231.xsd EX-101.SCH 1827290
95 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20251231_htm.xml XML 1928710
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41551 | Film No.: 26772384
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)